Literature DB >> 15875155

Increased plasma adiponectin concentrations are associated with microangiopathy in type 1 diabetic subjects.

S Hadjadj1, R Aubert, F Fumeron, F Pean, J Tichet, R Roussel, M Marre.   

Abstract

AIMS/HYPOTHESIS: Insulin resistance is related to an increased risk of diabetic retinopathy and nephropathy in type 1 diabetes. Patients with insulin resistance and/or macrovascular disease have abnormally low levels of adiponectin. The aim of this study was to investigate the relationships between adiponectin and renal and retinal diabetic complications in type 1 diabetic patients.
METHODS: In this 6-year prospective follow-up observational study, we evaluated the severity of retinopathy at baseline and determined the incident risk of microalbuminuria in 126 normoalbuminuric patients with type 1 diabetes. Each patient was age- and sex-matched to two non-diabetic control subjects.
RESULTS: Plasma adiponectin concentrations were significantly higher in diabetic subjects than in control subjects (p < 0.0001). The adiponectin concentration was significantly higher in patients with severe diabetic retinopathy than in those without (39.1+/-14.0 vs 29.0+/-13.0 microg/ml, p = 0.0005). The 18 patients who developed persistent microalbuminuria had higher adiponectin concentrations than the other patients (35.8+/-14.5 vs 30.6+/-13.7 microg/ml). Increased adiponectin concentrations were independently associated with the occurrence of microalbuminuria (p = 0.0158) after adjustment for baseline urinary albumin concentration (p = 0.004), sex (p = 0.0054), blood pressure (NS) and metabolic control (NS). CONCLUSIONS/
INTERPRETATION: The elevated adiponectin concentrations observed in subjects with microvascular disease may indicate an altered regulation of this adipocytokine in patients with complications associated with type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15875155     DOI: 10.1007/s00125-005-1747-x

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  33 in total

1.  Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy.

Authors:  H Sugimoto; K Shikata; M Matsuda; M Kushiro; Y Hayashi; K Hiragushi; J Wada; H Makino
Journal:  Diabetologia       Date:  1998-12       Impact factor: 10.122

2.  Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial.

Authors:  Katherine Esposito; Alessandro Pontillo; Carmen Di Palo; Giovanni Giugliano; Mariangela Masella; Raffaele Marfella; Dario Giugliano
Journal:  JAMA       Date:  2003-04-09       Impact factor: 56.272

3.  Renal effects of acute and chronic nitric oxide inhibition in experimental diabetes.

Authors:  A L Mattar; C K Fujihara; M O Ribeiro; G de Nucci; R Zatz
Journal:  Nephron       Date:  1996       Impact factor: 2.847

Review 4.  Adiponectin: a link between excess adiposity and associated comorbidities?

Authors:  Olavi Ukkola; Merja Santaniemi
Journal:  J Mol Med (Berl)       Date:  2002-09-10       Impact factor: 4.599

5.  Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study.

Authors:  Samy Hadjadj; Riadh Belloum; Béatrice Bouhanick; Yves Gallois; Gérard Guilloteau; Gilles Chatellier; François Alhenc-Gelas; Michel Marre
Journal:  J Am Soc Nephrol       Date:  2001-03       Impact factor: 10.121

6.  Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study.

Authors:  Trevor J Orchard; Yue-Fang Chang; Robert E Ferrell; Nancy Petro; Demetrius E Ellis
Journal:  Kidney Int       Date:  2002-09       Impact factor: 10.612

7.  Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study.

Authors:  Miranda T Schram; Nish Chaturvedi; Casper Schalkwijk; Francesco Giorgino; Pertti Ebeling; John H Fuller; Coen D Stehouwer
Journal:  Diabetes Care       Date:  2003-07       Impact factor: 19.112

8.  Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study.

Authors:  P Rossing; P Hougaard; K Borch-Johnsen; H H Parving
Journal:  BMJ       Date:  1996-09-28

9.  Incidence of cardiovascular disease in Type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland.

Authors:  J Tuomilehto; K Borch-Johnsen; A Molarius; T Forsén; D Rastenyte; C Sarti; A Reunanen
Journal:  Diabetologia       Date:  1998-07       Impact factor: 10.122

10.  Adiponectin stimulates production of nitric oxide in vascular endothelial cells.

Authors:  Hui Chen; Monica Montagnani; Tohru Funahashi; Iichiro Shimomura; Michael J Quon
Journal:  J Biol Chem       Date:  2003-08-27       Impact factor: 5.157

View more
  18 in total

1.  Relationship between ADIPOQ gene, circulating high molecular weight adiponectin and albuminuria in individuals with normal kidney function: evidence from a family-based study.

Authors:  C Menzaghi; S De Cosmo; M Copetti; L Salvemini; C De Bonis; D Mangiacotti; G Fini; F Pellegrini; V Trischitta
Journal:  Diabetologia       Date:  2011-01-13       Impact factor: 10.122

Review 2.  Review: adiponectin in retinopathy.

Authors:  Zhongjie Fu; Yan Gong; Chatarina Löfqvist; Ann Hellström; Lois E H Smith
Journal:  Biochim Biophys Acta       Date:  2016-05-04

3.  A New Optimized Percutaneous Access System for CIPII.

Authors:  Rosa Garcia-Verdugo; Michael Erbach; Oliver Schnell
Journal:  J Diabetes Sci Technol       Date:  2017-03-01

4.  Adiponectin, Insulin Sensitivity and Diabetic Retinopathy in Latinos With Type 2 Diabetes.

Authors:  Jane Z Kuo; Xiuqing Guo; Ronald Klein; Barbara E Klein; Pauline Genter; Kathryn Roll; Yang Hai; Mark O Goodarzi; Jerome I Rotter; Yii-Der Ida Chen; Eli Ipp
Journal:  J Clin Endocrinol Metab       Date:  2015-05-28       Impact factor: 5.958

5.  Low serum adiponectin levels in children and adolescents with diabetic retinopathy.

Authors:  Eser Tasci; Mehmet Nuri Ozbek; Neslihan Onenli-Mungan; Fatih Temiz; Ali Kemal Topaloglu; Bilgin Yuksel
Journal:  Eurasian J Med       Date:  2011-04

6.  Serum adipokine levels in patients with type 1 diabetes are associated with degree of obesity but only resistin is independently associated with atherosclerosis markers.

Authors:  Erieta Kollari; Ioanna Zografou; Christos Sampanis; Vasilios G Athyros; Triantafyllos Didangelos; Christos S Mantzoros; Asterios Karagiannis
Journal:  Hormones (Athens)       Date:  2021-10-30       Impact factor: 2.885

7.  Adiponectin and arterial stiffness in youth with type 1 diabetes: the SEARCH for diabetes in youth study.

Authors:  Amy S Shah; Lawrence M Dolan; Abigail Lauer; Cralen Davis; Dana Dabelea; Stephen R Daniels; Richard F Hamman; Santica Marcovina; R Paul Wadwa; Elaine M Urbina
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

8.  Adiponectin and catecholamine concentrations during acute exercise in children with type 1 diabetes.

Authors: 
Journal:  Pediatr Diabetes       Date:  2008-06       Impact factor: 4.866

9.  Effects of high levels of glucose on the steroidogenesis and the expression of adiponectin receptors in rat ovarian cells.

Authors:  Christine Chabrolle; Eric Jeanpierre; Lucie Tosca; Christelle Ramé; Joëlle Dupont
Journal:  Reprod Biol Endocrinol       Date:  2008-03-19       Impact factor: 5.211

10.  Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes.

Authors:  Ville-Petteri Mäkinen; Carol Forsblom; Lena M Thorn; Johan Wadén; Daniel Gordin; Outi Heikkilä; Kustaa Hietala; Laura Kyllönen; Janne Kytö; Milla Rosengård-Bärlund; Markku Saraheimo; Nina Tolonen; Maija Parkkonen; Kimmo Kaski; Mika Ala-Korpela; Per-Henrik Groop
Journal:  Diabetes       Date:  2008-06-10       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.